Last update 02 Oct 2025

Vusolimogene oderparepvec

Overview

Basic Info

Drug Type
Oncolytic virus
Synonyms
RP 1, RP-1
Action
stimulants, modulators
Mechanism
CSF-2R stimulants(Granulocyte-macrophage colony-stimulating factor receptor stimulants), GALV-GP R- modulators(GALV-GP R(-) modulators)
Inactive Indication-
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationPriority Review (United States), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MelanomaNDA/BLA
United States
21 Nov 2024
Unresectable MelanomaPhase 3
United States
11 Jul 2024
HemangiosarcomaPhase 2
United States
31 Oct 2025
Microsatellite instability-high cancerPhase 2
United States
30 Jan 2022
Basal Cell CarcinomaPhase 2
United States
15 May 2020
Merkel Cell CarcinomaPhase 2
United States
15 May 2020
Advanced Skin Squamous Cell CarcinomaPhase 2
United States
08 Oct 2019
Advanced Skin Squamous Cell CarcinomaPhase 2
Australia
08 Oct 2019
Advanced Skin Squamous Cell CarcinomaPhase 2
Bulgaria
08 Oct 2019
Advanced Skin Squamous Cell CarcinomaPhase 2
Canada
08 Oct 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
PD-L1
140
rlipgiscmv(euhinqmpso) = lbkbnwuslu dugxwovqwl (hvkpijcclp, 25.2% - 41.3)
Positive
08 Jul 2025
Phase 2
-
rtslvlmcod(kclhpgqkxl) = xeihidzoqa znmadgoebq (rcgodecvtu )
-
30 May 2025
Phase 3
Melanoma
BRAF V600-mutant
-
ftytffjveh(tzrzbhctmi) = bkmevamurk yhksapllyz (inpdnjdoxd )
Positive
30 May 2025
Phase 1/2
278
imogahwdaz(kvoxfordew) = mhyurxikkg mxgcksfbhl (tqiccsolio )
Positive
09 Apr 2025
Phase 2
Melanoma
Second line
140
qfxguufxjt(vstfgtnvkt) = rogpnxvzqc uegheqjdtx (mdvjinofme )
Positive
05 Nov 2024
Phase 2
Melanoma
Second line
140
RP1+nivolumab
xkqbtyyxfu(hrryqsfdth) = gnthcgsodv dplfvtuvqf (yfnryzruyz )
Positive
15 Sep 2024
RP1+nivolumab
(pts with primary anti–PD-1 resistance)
xkqbtyyxfu(hrryqsfdth) = wqwquphboi dplfvtuvqf (yfnryzruyz )
Phase 1/2
140
obtsfvhxql(wbzmdmkhrt) = craypcnism flyypugwzy (uaqnvkvkuz )
Positive
06 Jun 2024
Phase 1/2
156
lvlpnvrulb(kgpniutdst) = fjqrvxesuf pprsaquuhq (ildkgysvvc )
Positive
24 May 2024
Phase 1/2
23
kkororibpu(ktmspmgxjo) = vhzqiagubh ihmrepbmwa (aazcvcmvnd )
Positive
01 Apr 2024
Phase 1/2
23
ugpdtlfebv(gzyzvvxypk) = dedhnvtffy ndecwwkyqh (rqayztzjwh )
Positive
05 Dec 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free